OncoPharm

Lots to discuss from ESMO 2021 to new drug approvals. First, we discuss the updates in cervical cancer from ESMO (pembrolizumab with chemo) and the newly approved tisotumab-vedotin. Then, we discuss another new agent, mobocertinib and its scary QT prolongation profile as well as cabo-confusion in thyroid cancer. Finally, we discuss the potentially practice changing, but preliminary, data from ESMO in bladder cancer (VESPER) and HER2+ MBC (DESTINY-Breast03).

This discussion dives into the pivotal findings of the CASSIOPEIA Part 2 clinical trial, examining the role of daratumumab in treating myeloma after auto stem cell transplant. It tackles the effectiveness of this maintenance therapy and highlights critiques related to the trial's design. The ethical implications of using an observation control group spark thought-provoking debate, making for an engaging exploration of current myeloma treatments.

Discussing the use of mycophenolate mofetil (MMF) for ITP (https://www.nejm.org/doi/full/10.1056/NEJMoa2100596) as well as regulatory updates on atezolizumab and zanubrutinib.

Foundations of OncoPharm: Hypercalcemia of Malignancy (in under 10 minutes)

Belzutifan, the 1st hypoxia-inducible factor (HIF) inhibitor is FDA-approved. Plus, expanded indication approvals for nivolumab, dostarlimab, lenvatinib/pembrolizumab, & Ivosidenib. Finally, my Top 5 Rolling Stones Songs (14:30).

Looking into the data behind the FDA & CDC's allowance for a booster mRNA vaccine for immunocompromised patients.

A recent patient experience serves as a reminder than TKIs, like cabozantinib, can produce many "minor" toxicities that can really add up and affect QOL.

Two recent publications to discuss: 1. The publication of a study discussed on our ASCO '21 Pod on acalabrutinib vs. ibrutinib and patient implications (https://ascopubs.org/doi/pdf/10.1200/JCO.21.01210) 2. A good illustration of the "crossing of the curves" and interpreting Kaplan-Meier curves using alloHSCT vs. 5-aza in MDS patients. https://ascopubs.org/doi/pdf/10.1200/JCO.20.02724

Two breast cancer updates (pembrolizumab in TNBC and adjuvant AI duration) and two cGVHD updates (belumosudil and ruxolitinib).

The almost-award winning* Landmarks in OncoPharm series returns to discuss the landmark Armstrong et al 2006 NEJM paper on using intraperitoneal chemotherapy in stage III ovarian cancer. Link: https://www.nejm.org/doi/full/10.1056/nejmoa052985 *not really